Literature DB >> 10209662

Central nervous system sarcoidosis--diagnosis and management.

J P Zajicek1, N J Scolding, O Foster, M Rovaris, J Evanson, I F Moseley, J W Scadding, E J Thompson, V Chamoun, D H Miller, W I McDonald, D Mitchell.   

Abstract

A series of 68 patients with neurosarcoidosis is reported, with particular emphasis on clinical aspects, diagnosis and treatment. A classification system based on clinical diagnostic probability is proposed, consisting of probable and definite disease, the latter being dependent on finding sarcoid granulomas on nervous system histology, which was obtained in 12 patients (18%). The role of investigations, including magnetic resonance imaging (MRI), chest radiography, Kveim skin test, Gallium 67 isotope scanning and cerebrospinal fluid (CSF) studies, is considered. Sixty-two percent of patients presented with nervous system disease, most commonly affecting the optic nerve and chiasm. Other common presentations included cranial nerve palsies, spinal cord and brainstem manifestations. Investigations yielding most diagnostic information included the Kveim test (41/48, 85% positive), raised CSF protein and/or cells (50/62, 81%) and gallium 67 scan (14/31, 45%). Eleven out of 29 patients (38%) patients showed meningeal enhancement on MRI scanning and 43% of scans demonstrated multiple white-matter lesions. Mean follow-up for the group was 4.6 years. Forty-seven patients were seen for > 18 months, and over half of these patients progressed despite corticosteroid and other immunosuppressive therapies. The benefit of a large patient database prospectively studied, with extended follow-up is discussed in order to learn more about prognosis and advance therapy in neurosarcoidosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10209662     DOI: 10.1093/qjmed/92.2.103

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  161 in total

1.  A 59 year old man with progressive spinal cord and peripheral nerve dysfunction culminating in encephalopathy: Edinburgh advanced clinical neurology course, 1999.

Authors:  R Al-Shahi; C P Warlow; G H Jansen; C J Frijns; J van Gijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

Review 2.  Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature.

Authors:  K Warnatz; H H Peter; M Schumacher; L Wiese; A Prasse; F Petschner; P Vaith; B Volk; S M Weiner
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

3.  Neurosarcoidosis and the complexity in its differential diagnoses: a review.

Authors:  David R Spiegel; Kristyn Morris; Ubha Rayamajhi
Journal:  Innov Clin Neurosci       Date:  2012-04

Review 4.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

5.  Long-term outcomes of refractory neurosarcoidosis treated with infliximab.

Authors:  Fleur Cohen Aubart; Diane Bouvry; Damien Galanaud; Caroline Dehais; Guillaume Mathey; Dimitri Psimaras; Julien Haroche; Corinne Pottier; Miguel Hie; Alexis Mathian; Hervé Devilliers; Hilario Nunes; Dominique Valeyre; Zahir Amoura
Journal:  J Neurol       Date:  2017-03-04       Impact factor: 4.849

Review 6.  [Differential diagnosis of chronic inflammatory diseases of the central nervous system. Cerebrospinal fluid diagnosis and immunological parameters].

Authors:  D Reske; H-F Petereit
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

Review 7.  Ocular Sarcoidosis.

Authors:  Sirichai Pasadhika; James T Rosenbaum
Journal:  Clin Chest Med       Date:  2015-12       Impact factor: 2.878

Review 8.  Neuro-otological syndromes for the neurologist.

Authors:  J Overell; A Lindahl
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

Review 9.  Neurosarcoidosis.

Authors:  Dakshinamurty Gullapalli; Lawrence H Phillips
Journal:  Curr Neurol Neurosci Rep       Date:  2004-11       Impact factor: 5.081

10.  Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil.

Authors:  Michael Moravan; Benjamin M Segal
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.